Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 1
1960 1
1961 3
1963 1
1964 3
1965 2
1966 1
1967 4
1968 3
1969 2
1970 5
1971 4
1972 1
1973 1
1975 2
1976 2
1977 2
1978 5
1980 3
1981 1
1982 3
1983 5
1984 7
1985 10
1986 17
1987 8
1988 8
1989 7
1990 3
1991 8
1992 3
1993 3
1994 4
1995 4
1996 3
1997 1
1998 8
1999 8
2000 8
2001 10
2002 8
2003 14
2004 11
2005 11
2006 23
2007 18
2008 22
2009 18
2010 19
2011 32
2012 25
2013 30
2014 23
2015 30
2016 38
2017 46
2018 34
2019 40
2020 58
2021 82
2022 80
2023 71
2024 75
2025 70
2026 30

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

977 results

Results by year

Filters applied: . Clear all
Page 1
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C, Bradbury P, Moskovitz M, Katgi N, Tomasini P, Zer A, Girard N, Cuppens K, Han JY, Wu SY, Baijal S, Mansfield AS, Kuo CH, Nishino K, Lee SH, Planchard D, Baik C, Li M, Ansell P, Xia S, Bolotin E, Looman J, Ratajczak C, Lu S. Camidge DR, et al. Among authors: nishino k. J Clin Oncol. 2024 Sep 1;42(25):3000-3011. doi: 10.1200/JCO.24.00720. Epub 2024 Jun 6. J Clin Oncol. 2024. PMID: 38843488 Free PMC article. Clinical Trial.
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.
Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, Ou SI, Rodon J, Rha SY, Nishino K, Duruisseaux M, Park JO, Neuzillet C, Liu SV, Weinberg BA, Cleary JM, Calvo E, Umemoto K, Nagasaka M, Springfeld C, Bekaii-Saab T, O'Kane GM, Opdam F, Reiss KA, Joe AK, Wasserman E, Stalbovskaya V, Ford J, Adeyemi S, Jain L, Jauhari S, Drilon A; eNRGy Investigators. Schram AM, et al. Among authors: nishino k. N Engl J Med. 2025 Feb 6;392(6):566-576. doi: 10.1056/NEJMoa2405008. N Engl J Med. 2025. PMID: 39908431 Free PMC article. Clinical Trial.
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O, Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K, Okamoto I. Shiraishi Y, et al. Among authors: nishino k. JAMA Oncol. 2024 Mar 1;10(3):315-324. doi: 10.1001/jamaoncol.2023.5258. JAMA Oncol. 2024. PMID: 38127362 Free PMC article. Clinical Trial.
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Nishino K, Yoh K, Shih JY, Chik JYK, Moro-Sibilot D, Puri T, Chacko Varughese S, Frimodt-Moller B, Visseren-Grul C, Reck M. Nakagawa K, et al. Among authors: nishino k. J Thorac Oncol. 2025 Apr;20(4):487-499. doi: 10.1016/j.jtho.2024.11.032. Epub 2024 Nov 30. J Thorac Oncol. 2025. PMID: 39622410 Free article. Clinical Trial.
The Rubicon-WIPI axis regulates exosome biogenesis during ageing.
Yanagawa K, Kuma A, Hamasaki M, Kita S, Yamamuro T, Nishino K, Nakamura S, Omori H, Kaminishi T, Oikawa S, Kato Y, Edahiro R, Kawagoe R, Taniguchi T, Tanaka Y, Shima T, Tabata K, Iwatani M, Bekku N, Hanayama R, Okada Y, Akimoto T, Kosako H, Takahashi A, Shimomura I, Sakata Y, Yoshimori T. Yanagawa K, et al. Among authors: nishino k. Nat Cell Biol. 2024 Sep;26(9):1558-1570. doi: 10.1038/s41556-024-01481-0. Epub 2024 Aug 22. Nat Cell Biol. 2024. PMID: 39174742
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.
Miura S, Tanaka H, Misumi T, Yoshioka H, Tokito T, Fukuhara T, Sato Y, Shiraishi Y, Naoki K, Akamatsu H, Yamaguchi O, Yokoyama T, Kuyama S, Nishino K, Furuya N, Kurata T, Kato T, Ikeda S, Horinouchi H, Ichihara E, Mori M, Takiguchi Y, Tanaka K, Goto Y, Okamoto H; Thoracic Oncology Research Group and all ACHILLES investigators. Miura S, et al. Among authors: nishino k. J Clin Oncol. 2025 Jun 20;43(18):2049-2058. doi: 10.1200/JCO-24-02007. Epub 2025 Apr 16. J Clin Oncol. 2025. PMID: 40239133 Clinical Trial.
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions.
Kim DW, Schram AM, Hollebecque A, Nishino K, Macarulla T, Rha SY, Duruisseaux M, Liu SV, Al Hallak MN, Umemoto K, Wesseler C, Cleary JM, Springfeld C, Neuzillet C, Joe A, Jauhari S, Ford J, Goto K. Kim DW, et al. Among authors: nishino k. Future Oncol. 2024;20(16):1057-1067. doi: 10.2217/fon-2023-0824. Epub 2024 Feb 13. Future Oncol. 2024. PMID: 38348690 Free PMC article.
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.
Kato Y, Udagawa H, Matsumoto S, Izumi H, Ohe Y, Kato T, Nishino K, Miyamoto S, Kawana S, Chikamori K, Shingyoji M, Sato Y, Takada Y, Toyozawa R, Azuma K, Tanaka Y, Sakai T, Shibata Y, Sugiyama E, Nosaki K, Zenke Y, Umemura S, Yoh K, Seike M, Goto K. Kato Y, et al. Among authors: nishino k. Lung Cancer. 2024 Nov;197:107992. doi: 10.1016/j.lungcan.2024.107992. Epub 2024 Oct 13. Lung Cancer. 2024. PMID: 39423763
HKDC1, a target of TFEB, is essential to maintain both mitochondrial and lysosomal homeostasis, preventing cellular senescence.
Cui M, Yamano K, Yamamoto K, Yamamoto-Imoto H, Minami S, Yamamoto T, Matsui S, Kaminishi T, Shima T, Ogura M, Tsuchiya M, Nishino K, Layden BT, Kato H, Ogawa H, Oki S, Okada Y, Isaka Y, Kosako H, Matsuda N, Yoshimori T, Nakamura S. Cui M, et al. Among authors: nishino k. Proc Natl Acad Sci U S A. 2024 Jan 9;121(2):e2306454120. doi: 10.1073/pnas.2306454120. Epub 2024 Jan 3. Proc Natl Acad Sci U S A. 2024. PMID: 38170752 Free PMC article.
Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial.
Yu Y, Zhou J, Li X, Goto K, Min X, Nishino K, Cui J, Wu L, Sakakibara J, Shu Y, Dong X, Li L, Yoneshima Y, Zhou C, Li X, Zhang Y, Huang D, Zang A, Zhang W, Wang X, Zhang L, Bai C, Fang J, Cao L, Zhao Y, Yu Y, Shi M, Zhong D, Li F, Li M, Wu Q, Zhou J, Sun M, Lu S. Yu Y, et al. Among authors: nishino k. EClinicalMedicine. 2023 Apr 6;59:101952. doi: 10.1016/j.eclinm.2023.101952. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37096188 Free PMC article.
977 results